Imugene Ltd (IMU)

Sydney
0.26
0.00(0.00%)
  • Volume:
    50,807,907
  • Bid/Ask:
    0.255/0.26
  • Day's Range:
    0.248 - 0.29

IMU Overview

Prev. Close
0.26
Day's Range
0.248 - 0.29
Revenue
5.95M
Open
0.26
52 wk Range
0.028 - 0.29
EPS
0
Volume
50,807,907
Market Cap
1.23B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
13,599,331
P/E Ratio
-
Beta
2.77
1-Year Change
828.57%
Shares Outstanding
4,740,920,126
Next Earnings Date
-
What is your sentiment on Imugene Ltd?
or
Market is currently closed. Voting is open during market hours.

Imugene Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong SellBuyStrong BuyStrong Buy
SummaryStrong BuyNeutralBuyStrong BuyStrong Buy

Imugene Ltd Company Profile

Imugene Ltd Company Profile

Employees
0
Market
Australia

Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.

Read More
  • Ready to ride this rocket
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.